NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Equillium, Inc. (EQ) Stock Analysis

Equillium, Inc. (EQ) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

EQ

$1.42

+$0.04 (+2.90%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EQ with… →

EQ Key Statistics

As of Oct 21, 2026
Trading
Open
$1.40
Previous Close
$1.38
Day's Range
1.39–1.51
52-Week Range
0.76–3.54
Volume
442.54K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.92
Valuation
Market Cap
$90.04M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.14
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$22.40M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.41M
1-Year Return
+2.90%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
599.58K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EQ closed at $1.42, +2.90% over 1 year.

Equillium, Inc. (EQ) has a market capitalization of $90.04M.

In fiscal 2025, EQ reported revenue of $0.00.

EQ Stock Return by Calendar Year

Equillium, Inc. (EQ) return since Oct 2018: what $10,000 became

1 year
$10,000 $10,290
+2.90%
5 years
$10,000 $2,355
−76.45%
Since Oct 2018
$10,000 $1,014
−89.86%

If you had invested $10,000 in Equillium, Inc. (EQ) at the close on October 12, 2018, the earliest close on record here, it would have been worth $1,014 at the close on October 21, 2026: −89.86% in total, −24.81% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.39%
2025+106.67%
2024+4.17%
2023−32.08%
2022−71.88%
2021−29.53%
2020+58.28%
2019−58.58%
2018 (partial year)−41.71%

As of October 21, 2026.

EQ Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$22.40M—
2024$41.10M−$8.07M−19.6%
2023$36.08M−$13.34M−37.0%
2022$15.76M−$62.43M−396.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$23.63M−$22.40M—
2024$41.10M—−$8.27M−$8.07M−19.6%
2023$36.08M—−$14.52M−$13.34M−37.0%
2022$15.76M—−$39.03M−$62.43M−396.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Equillium, Inc. (EQ) at $90.04M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 14 employees.

Over the past 52 weeks the price has ranged from $0.76 to $3.54. The most recent close on file for EQ is $1.42, dated October 21, 2026. That is +$0.04 (+2.90%) against the previous close. The latest close sits 86.84% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $41.10M, that is a change of −100.00%. The same year closed with a net loss of $22.40M. Trailing earnings per share are −0.14.

Across the 4 fiscal years on file, revenue moves from $15.76M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 1.92. Daily returns over the trailing 8 years annualize to a volatility of 282.93%. The trailing one-year total return is +2.90%. Across 5 years the annualized return works out at −25.12%.

Growth & Income

The record shows no dividend for EQ.

2026 is still running; the total return is −8.39% year to date. The strongest complete calendar year on file is 2025 at +106.67%; the weakest is 2022 at −71.88%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Equillium, Inc. (EQ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Equillium, Inc. EQ $90.04M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Equillium, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Visit website →